In vitro evaluation of concentration, labeling effectiveness and stability for I-131-labeled radioimmunoassay ligand using real-time detection technology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10335293" target="_blank" >RIV/00216208:11160/17:10335293 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/17:10335293

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1002/jlcr.3478" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1002/jlcr.3478</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/jlcr.3478" target="_blank" >10.1002/jlcr.3478</a>

Jazyk výsledku

angličtina

Název v původním jazyce

In vitro evaluation of concentration, labeling effectiveness and stability for I-131-labeled radioimmunoassay ligand using real-time detection technology

Popis výsledku v původním jazyce

Radioimmunoassay belongs to the analytical method enabling highly specific and sensitive quantification of molecules. The verification of the real-time radioimmunoassay technology usefulness for ligand-quality characteristics evaluation such as concentration, influence of radiolabeling on binding affinity and stability was estimated. The anti-epidermal growth factor receptor antibody I-131-cetuximab was employed as the ligand antibody. The concentration of I-131-cetuximab was derived from the shape of binding curves coming from the ligand-receptor interaction. The binding curves also allowed the estimation of I-131-cetuximab binding affinity for different radiolabeling procedures (incubation times 1, 5, and 10minutes) in stability testing up to 96hours at 4 degrees C. The stability testing also included comparative analysis by size exclusion high-performance liquid chromatography. The assessment of cetuximab concentrations using real-time method showed acceptable accordance between real and calculated values. The real-time method revealed that 1-minute radiolabeling proved to be the optimal incubation time for direct radioiodination of cetuximab. Stability testing showed the significant change in radioligand affinity by one order at the longest incubation times (72 and 96hours). Characterization of stability and binding behavior of radiolabeled monoclonal antibodies by the verified real-time method before use in other assays may be employed to eliminate variability and suboptimal antibody performance.

Název v anglickém jazyce

In vitro evaluation of concentration, labeling effectiveness and stability for I-131-labeled radioimmunoassay ligand using real-time detection technology

Popis výsledku anglicky

Radioimmunoassay belongs to the analytical method enabling highly specific and sensitive quantification of molecules. The verification of the real-time radioimmunoassay technology usefulness for ligand-quality characteristics evaluation such as concentration, influence of radiolabeling on binding affinity and stability was estimated. The anti-epidermal growth factor receptor antibody I-131-cetuximab was employed as the ligand antibody. The concentration of I-131-cetuximab was derived from the shape of binding curves coming from the ligand-receptor interaction. The binding curves also allowed the estimation of I-131-cetuximab binding affinity for different radiolabeling procedures (incubation times 1, 5, and 10minutes) in stability testing up to 96hours at 4 degrees C. The stability testing also included comparative analysis by size exclusion high-performance liquid chromatography. The assessment of cetuximab concentrations using real-time method showed acceptable accordance between real and calculated values. The real-time method revealed that 1-minute radiolabeling proved to be the optimal incubation time for direct radioiodination of cetuximab. Stability testing showed the significant change in radioligand affinity by one order at the longest incubation times (72 and 96hours). Characterization of stability and binding behavior of radiolabeled monoclonal antibodies by the verified real-time method before use in other assays may be employed to eliminate variability and suboptimal antibody performance.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Labelled Compounds and Radiopharmaceuticals

ISSN

0362-4803

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

80-86

Kód UT WoS článku

000393835900010

EID výsledku v databázi Scopus

2-s2.0-85006922964